Log in

NASDAQ:CNCEConcert Pharmaceuticals Stock Price, Forecast & News

$9.27
-0.33 (-3.44 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$9.13
Now: $9.27
$9.83
50-Day Range
$7.88
MA: $9.77
$11.52
52-Week Range
$5.36
Now: $9.27
$13.09
Volume148,594 shs
Average Volume147,818 shs
Market Capitalization$274.86 million
P/E RatioN/A
Dividend YieldN/A
Beta0.91
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.
Read More
Concert Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CNCE
CUSIPN/A
Phone781-860-0045

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.08 million
Book Value$4.26 per share

Profitability

Net Income$-78,170,000.00
Net Margins-97,236.70%

Miscellaneous

Employees71
Market Cap$274.86 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.

Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

How has Concert Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Concert Pharmaceuticals' stock was trading at $8.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CNCE shares have increased by 11.0% and is now trading at $9.27. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Concert Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Concert Pharmaceuticals.

When is Concert Pharmaceuticals' next earnings date?

Concert Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Concert Pharmaceuticals.

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals Inc (NASDAQ:CNCE) issued its earnings results on Thursday, April, 30th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.74) by $0.04. The biotechnology company had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.02 million. Concert Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 97,236.70%. View Concert Pharmaceuticals' earnings history.

What price target have analysts set for CNCE?

7 brokers have issued twelve-month target prices for Concert Pharmaceuticals' stock. Their forecasts range from $10.00 to $30.00. On average, they expect Concert Pharmaceuticals' share price to reach $19.50 in the next twelve months. This suggests a possible upside of 110.4% from the stock's current price. View analysts' price targets for Concert Pharmaceuticals.

Has Concert Pharmaceuticals been receiving favorable news coverage?

Headlines about CNCE stock have been trending negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Concert Pharmaceuticals earned a daily sentiment score of -2.8 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an effect on the company's share price in the next few days. View the latest news about Concert Pharmaceuticals.

Who are some of Concert Pharmaceuticals' key competitors?

What other stocks do shareholders of Concert Pharmaceuticals own?

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the following people:
  • Mr. Richard H. Aldrich Mba, Co-Founder & Chairman (Age 65)
  • Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 59)
  • Ms. Nancy Stuart, Chief Operating Officer (Age 61)
  • Dr. James V. Cassella, Chief Devel. Officer (Age 64)
  • Mr. Marc A. Becker, Chief Financial Officer (Age 47)

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $9.27.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $274.86 million and generates $1.08 million in revenue each year. The biotechnology company earns $-78,170,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe.

What is Concert Pharmaceuticals' official website?

The official website for Concert Pharmaceuticals is www.concertpharma.com.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.